A multicenter, randomized, double-blind, 'factorial' design study to evaluate the lipid-altering efficacy and safety of coadministered MK0524B tablets [niacin/laropiprant/simvastatin] in patients with primary hypercholesterolemia or mixed hyperlipidemia [type V hyperlipoproteinaemia]

Trial Profile

A multicenter, randomized, double-blind, 'factorial' design study to evaluate the lipid-altering efficacy and safety of coadministered MK0524B tablets [niacin/laropiprant/simvastatin] in patients with primary hypercholesterolemia or mixed hyperlipidemia [type V hyperlipoproteinaemia]

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Laropiprant/niacin/simvastatin (Primary) ; Niacin/laropiprant; Simvastatin
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type V; Lipid metabolism disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms Factorial
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 May 2008 Results reported at WCC 2008
    • 11 Mar 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top